Workspace 05 · Medicines, Pharmacovigilance & Lifecycle AI

Medicine lifecycle AI is useful when benefit-risk evidence stays traceable.

This workspace maps AI in discovery translation, medical writing, pharmacovigilance, benefit-risk review, regulatory operations, supply, quality, lifecycle maintenance, and post-market evidence.

Focus: medicine lifecycle · PV · benefit-riskRisk: signal distortion and weak traceabilityBridge: case · evidence · action
Medicines traceCaseSignalBenefitRiskActionReviewAIsystemsource to workflow to evidence to review
AI in Healthcare/Medicines, Pharmacovigilance & Lifecycle AI
/ workspace

Medicines, Pharmacovigilance & Lifecycle AI workspace.

9 chapter surfaces

This workspace maps AI in discovery translation, medical writing, pharmacovigilance, benefit-risk review, regulatory operations, supply, quality, lifecycle maintenance, and post-market evidence.

/ map

Source-to-use operating map.

how this workspace reads AI
Operating map
InventoryList the AI systems, actors, records, and workflows in scope.
RiskClassify impact, uncertainty, affected users, and plausible harms.
EvidenceConnect claims to validation, source data, limitations, and monitoring.
ReviewKeep owners, decisions, revisions, and open questions visible.
Chapter 01

Overview

The overview defines the boundary of Medicines, Pharmacovigilance & Lifecycle AI: what belongs in scope, what remains outside the claim, and what evidence has to travel with any public or operational interpretation.

source-backedRead →
Chapter 02

Use Cases

Use cases in Medicines are sorted by the decision they affect and the evidence they require, not by the attractiveness of the tool demonstration.

source-backedRead →
Chapter 03

Data Substrate

The data substrate for Medicines determines what the model can know, what it misses, what it amplifies, and what remains reviewable later.

source-backedRead →
Chapter 04

Model Lifecycle

The lifecycle view treats AI in Medicines as a managed capability: design, validation, deployment, monitoring, update, rollback, and retirement.

source-backedRead →
Chapter 05

Validation & Evidence

Validation evidence for Medicines connects technical performance to the real workflow, population, user, and decision context.

source-backedRead →
Chapter 06

Governance & Risk

Governance and risk for Medicines define who can approve use, what harms are plausible, which controls apply, and when use is paused or escalated.

source-backedRead →
Chapter 07

Operations & Adoption

Operations and adoption in Medicines focus on whether teams can use the system consistently, challenge it safely, and learn from real use.

source-backedRead →
Chapter 08

Market & Actors

The market and actor layer for Medicines maps who builds, sells, deploys, uses, monitors, audits, and regulates the capability.

source-backedRead →
Chapter 09

Updates & Assets

The updates and assets layer keeps Medicines alive through weekly signals, source maps, checklists, explainers, and revision notes.

source-backedRead →
/ sources

Source anchors and claim boundary.

official first

These anchors support the source layer for this workspace. iFeed interpretation stays separate from source facts and does not replace legal, regulatory, clinical, or product-specific advice.